A new research document with title ‘Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline Review, H2 2017’ covering detailed analysis, Competitive landscape, forecast and strategies.
The latest Pharmaceutical and Healthcare disease pipeline guide Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline Review, H2 2017, provides an overview of the Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline landscape.
Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease. Nonalcoholic fatty liver disease is common and, for most people, causes no signs and symptoms and no complications. But in some people with nonalcoholic fatty liver disease, the fat that accumulates can cause inflammation and scarring in the liver. The most common symptoms that bring NAFLD to medical attention are malaise, fatigue, and right upper quadrant or diffuse abdominal discomfort.
Request a sample report @ https://www.htfmarketreport.com/sample-report/575245-non-alcoholic-fatty-liver-disease-4
The Pharmaceutical and Healthcare latest pipeline guide Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 15, 11, 22, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from The proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
– The pipeline guide provides a snapshot of the global therapeutic landscape of Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal).
– The pipeline guide reviews pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal)
Buy this report @ https://www.htfmarketreport.com/buy-now?format=1&report=575245
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned in the Report
Akcea Therapeutics Inc
Bird Rock Bio Inc
Boehringer Ingelheim GmbH
Can-Fite BioPharma Ltd
Cerenis Therapeutics Holding SA
CJ HealthCare Corp
Conatus Pharmaceuticals Inc
Corcept Therapeutics Inc
CymaBay Therapeutics Inc
Daewoong Pharmaceutical Co Ltd
Dimerix Bioscience Pty Ltd
Dr. Falk Pharma GmbH
Enanta Pharmaceuticals Inc
Galmed Pharmaceuticals Ltd
Gemphire Therapeutics Inc
Gilead Sciences Inc
Huons Co Ltd
Kyorin Pharmaceutical Co Ltd
Matinas BioPharma Holdings Inc
Miyarisan Pharmaceutical Company Ltd
Nordic Bioscience A/S
NovaTarg Therapeutics Inc
Ocera Therapeutics Inc
Renova Therapeutics Inc
Sancilio & Company Inc
Shenzhen HighTide Biopharmaceutical Ltd
TaiwanJ Pharmaceuticals Co Ltd
TCM Biotech International Corp
Zydus Cadila Healthcare Ltd
Get customization & check discount for report @ https://www.htfmarketreport.com/request-discount/575245-non-alcoholic-fatty-liver-disease-4
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Global Markets Direct Report Coverage 7
Non Alcoholic Fatty Liver Disease (NAFLD) – Overview 8
Non Alcoholic Fatty Liver Disease (NAFLD) – Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 14
Products under Development by Companies 15
Products under Development by Universities/Institutes 18
Non Alcoholic Fatty Liver Disease (NAFLD) – Therapeutics Assessment 19
Assessment by Target 19
Assessment by Mechanism of Action 23
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Non Alcoholic Fatty Liver Disease (NAFLD) – Companies Involved in Therapeutics Development 31
Akcea Therapeutics Inc 31
Allergan Plc 31
Ardelyx Inc 32
AstraZeneca Plc 32
Betagenon AB 33
Bird Rock Bio Inc 33
Boehringer Ingelheim GmbH 34
Can-Fite BioPharma Ltd 34
Cerenis Therapeutics Holding SA 35
CJ HealthCare Corp 35
Conatus Pharmaceuticals Inc 36
Corcept Therapeutics Inc 36
CymaBay Therapeutics Inc 37
Daewoong Pharmaceutical Co Ltd 37
Dimerix Bioscience Pty Ltd 38
Dr. Falk Pharma GmbH 38
DURECT Corp 39
Enanta Pharmaceuticals Inc 39
Eternygen GmbH 40
Galmed Pharmaceuticals Ltd 40
Gemphire Therapeutics Inc 41
Genfit SA 41
Gilead Sciences Inc 42
Huons Co Ltd 42
Immuron Ltd 43
Kyorin Pharmaceutical Co Ltd 43
Matinas BioPharma Holdings Inc 44
Metacrine Inc 44
Miyarisan Pharmaceutical Company Ltd 45
Nordic Bioscience A/S 45
NovaTarg Therapeutics Inc 46
Ocera Therapeutics Inc 46
Pfizer Inc 47
Renova Therapeutics Inc 47
Sancilio & Company Inc 48
Shenzhen HighTide Biopharmaceutical Ltd 48
TaiwanJ Pharmaceuticals Co Ltd 49
TCM Biotech International Corp 49
Zydus Cadila Healthcare Ltd 50
Non Alcoholic Fatty Liver Disease (NAFLD) – Drug Profiles 51
(leucine + metformin hydrochloride + sildenafil citrate) – Drug Profile 51
(leucine + PDE5 Inhibitor) – Drug Profile 53
AC-261066 – Drug Profile 54
View Detailed Table of Content @ https://www.htfmarketreport.com/reports/575245-non-alcoholic-fatty-liver-disease-4
Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.
CRAIG FRANCIS (PR & Marketing Manager)
Ph: +1 (206) 317 1218